Key facts

Invented name
Trecondi
Active Substance
Treosulfan
Therapeutic area
  • Immunology-Rheumatology-Transplantation
  • Oncology
Decision number
P/0346/2020
PIP number
EMEA-000883-PIP01-10-M05
Pharmaceutical form(s)
Powder for solution
Condition(s) / indication(s)
Conditioning treatment prior to haematopoietic-progenitor-cell transplantation
Route(s) of administration
Intravenous use
Contact for public enquiries

medac Gesellschaft für klinische Spezialpräparate mbH

Germany
Tel. +49 (0) 401380060
E-mail: dra@medac.de

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance procedure number
EMEA-C-000883-PIP01-10-M05
Compliance opinion date
Compliance outcome
Positive

Decision

P/0346/2020: EMA decision of 9 September 2020 on the acceptance of a modification of an agreed paediatric investigation plan for treosulfan (Trecondi), (EMEA-000883-PIP01-10-M05)

How useful do you find this page?